Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma

Carfilzomib, a selective proteasome inhibitor (PI), is approved for the treatment of patients with relapsed or refractory multiple myeloma (MM). Combination regimens incorporating a PI and immunomodulatory drug (IMiD) have been associated with deep responses and extended survival in patients with ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Landgren, Ola, Sonneveld, Pieter, Jakubowiak, Andrzej, Mohty, Mohamad, Iskander, Karim S., Mezzi, Khalid, Siegel, David S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756042/
https://www.ncbi.nlm.nih.gov/pubmed/31341235
http://dx.doi.org/10.1038/s41375-019-0517-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756042/
https://www.ncbi.nlm.nih.gov/pubmed/31341235
http://dx.doi.org/10.1038/s41375-019-0517-6

Ejemplares similares